J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience
Preetesh Jain,Hagop M. Kantarjian,Jorge E. Cortes,Elias Jabbour,Stefan Faderl,William G. Wierda,Guillermo Garcia-Manero,Alessandra Ferrajoli,Srdan Verstovsek,Jan A. Burger,Luis Fayad,Jorge E. Romaguera,Rebecca Garris,Farhad Ravandi,Susan O'Brien,Deborah A. Thomas +15 more
TL;DR: The incorporation of rituximab into the hyper-CVAD regimen has improved outcomes for de novo BL/B-ALL, with achievement of respectable cure rates and investigation of other novel monoclonal antibodies such as blinatumomab or inotuzumab for BL/Bsall is clearly warranted.
Journal ArticleDOI
Analysis of Quality of Life and Well-being from the Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Older Patients with Treatment-naïve CLL (RESONATE-2TM)
Thomas J. Kipps,Paolo Ghia,Alessandra Tedeschi,Paul M. Barr,Tadeusz Robak,Carolyn Owen,Osnat Bairey,Peter Hillmen,Nancy L. Bartlett,Jianyong Li,David Simpson,Sebastian Grosicki,Stephen Deverux,Helen McCarthy,Steven Coutre,Fritz Offner,Carol Moreno,Cathy Zhou,Lori Styles,Danelle F. James,Jan A. Burger +20 more
Journal ArticleDOI
Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia
Candida Vitale,Maria Ciccone,Christina Hinojosa,Michael J. Keating,Naveen Pemmaraju,Susan O'Brien,William G. Wierda,Deborah A. Thomas,Gautam Borthakur,Maro Ohanian,Jan A. Burger,Alessandra Ferrajoli +11 more
TL;DR: A phase II study to investigate the activity and toxicity of ofatumumab in older unfit patients with CLL/SLL and observed complete responses (CR) in 4 patients (16%), and partial responses in 6 patients (56%).
Journal ArticleDOI
Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML).
Elias Jabbour,Hagop M. Kantarjian,A. Megan Cornelison,Tapan M. Kadia,Mary-Alma Welch,Lynne V. Abruzzo,Jan A. Burger,Alessandra Ferrajoli,Guillermo Garcia-Manero,Jorge E. Cortes +9 more
TL;DR: It is concluded that cytogenetic abnormalities occur in Ph-negative cells in a small fraction of pts treated with 2 nd TKIs and usually have no clinical significance, but in rare instances they could signal the emergence of a new malignant clone.
Journal ArticleDOI
The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.
Paolo Strati,Feng Wang,Francesco Paolo Tambaro,Philip A. Thompson,Jan A. Burger,Nitin Jain,Alessandra Ferrajoli,Prithviraj Bose,Zeev Estrov,Michael J. Keating,Andrew Futreal,Koichi Takahashi,William G. Wierda +12 more
TL;DR: K and high CK were defined as the presence of ≥3 and ≥5, clonal chromosome abnormalities, respectively, occurring in at least 2 out of 20 cells, either structural or numerical (Baliakas et al, 2019).